February 2024 in “PubMed” The new minoxidil lotion using Aloplus Total is stable and can be mixed with other ingredients for treating hair loss.
November 2003 in “Journal of Neurochemistry” Allopregnanolone may enhance alcohol's effects on dopamine neurons, influencing addiction risk.
9 citations
,
May 2019 in “Journal of dermatological treatment” Apremilast helps regrow hair in hard-to-treat alopecia areata.
6 citations
,
April 2015 in “Behavioural Brain Research” Finasteride worsens stress effects on sensory processes, possibly linking to anxiety/depression.
4 citations
,
November 2018 in “Journal of pharmacological sciences” Mild exercise reduces pain in older rats through a brain chemical, while intense exercise reduces pain in all rats through a different pain-blocking process.
9 citations
,
May 2011 in “Hormones and Behavior” Allopregnanolone, a progesterone metabolite, helps reduce restraint effects on behavior.
2 citations
,
August 2017 in “Drug and therapeutics bulletin” Strontium ranelate is no longer available for treatment.
12 citations
,
August 2018 in “Psychiatry research” Estazolam reduces anxiety-like behavior in PTSD by increasing allopregnanolone levels.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for alopecia areata patients over 72 months.
2 citations
,
December 2019 in “Neurobiology of Stress” Changing allopregnanolone levels in baby rats affects their adult behavior and alcohol use.
August 2026 in “Canadian Journal of Health Technologies” Litfulo is recommended for treating severe alopecia areata in people 12 and older, as it helps hair regrowth.
March 2023 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.
1 citations
,
January 2013 in “Digital Scholarship - UNLV (University of Nevada Reno)” Targeting neurosteroids may help prevent drug relapse.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
4 citations
,
November 2023 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is safe for treating alopecia areata for up to 48 weeks.
1 citations
,
November 2025 in “American Journal of Clinical Dermatology” Ritlecitinib is generally safe for long-term use in treating alopecia areata.
Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
76 citations
,
July 2009 in “Neuroscience” Neurosteroids like allopregnanolone help control cell death and growth in the developing fetal brain.
1 citations
,
June 2026 in “Dermato” Ritlecitinib is effective for treating alopecia areata, showing significant hair regrowth with mild side effects.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
40 citations
,
March 2003 in “The journal of small animal practice/Journal of small animal practice” Trilostane helped a dog with an adrenal tumor feel better and stay healthy.
March 2025 in “Journal of Investigative Dermatology” 1 citations
,
January 2013 in “UNICA IRIS Institutional Research Information System (University of Cagliari)” Hormonal contraceptives may reduce social behavior and sexual motivation by lowering allopregnanolone levels.
24 citations
,
December 2012 in “Behavioural Brain Research” Changing Allopregnanolone levels in newborns affects adult behavior and anxiety.
March 2026 in “American Journal of Clinical Dermatology” Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
December 2025 in “Actas Dermo-Sifiliográficas” Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
April 2023 in “Journal of Investigative Dermatology” ALRN-6924 can protect hair follicles from chemotherapy damage by temporarily stopping cell division.